Le Lézard
Classified in: Health, Business
Subjects: PDT, RCN

Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina


LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.

The move to Research Triangle Park follows Immunovia's successful model development study, announced on April 22, 2024, and the successful completion of the discovery phase for its next-generation test in November 2023. Following these successes, the company will focus on confirming the analytical validity of its new test and conducting a large clinical validation study. This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts. The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

"Research Triangle Park offers access to top talent at a reasonable cost. Moving to a smaller lab in RTP is a key aspect of our ongoing efforts to be a leaner, more efficient company", says Jeff Borcherding, CEO and President of Immunovia.

For more information, please contact:
Jeff Borcherding
CEO and President
[email protected]

Karin Almqvist Liwendahl
Chief Financial Officer
[email protected]
+46 709 11 56 08

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit?www.immunovia.com 

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/immunovia-ab/r/immunovia-streamlines-lab-operations-with-move-to-research-triangle-park--north-carolina,c3969794

The following files are available for download:

https://mb.cision.com/Main/13121/3969794/2767296.pdf

Press release (PDF)

 

SOURCE Immunovia AB


These press releases may also interest you

at 21:23
Genesis Reports Voting Results of Election of Directors
Genesis Land Development Corp. ("Genesis") is pleased to report that at its annual meeting of shareholders held on May 14, 2024 that each of the nominees proposed by management as a director of Genesis were elected as directors. The detailed...

at 21:15
Nexus Industrial REIT Announces First Quarter 2024 Financial Results and Annual Meeting Voting Results
Nexus Industrial REIT (the "REIT") announced today its results for the first quarter ended March 31, 2024. "This quarter we continued to make progress as a Canada-focused pure-play industrial REIT" commented Kelly Hanczyk, CEO of Nexus...

at 21:13
Mason Capital Announces Tender Offer for Any and All of (i) the Outstanding American Depositary Shares (the "ADSs"), each representing 4,000 Ordinary Shares, Nominal Value 0.01 DKK of Forward Pharma A/S (the "Ordinary Shares") for a Purchase Price of $437.00 per ADS and (ii) the Outstanding Ordinary Shares for a Purchase Price of 0.76 DKK per Ordinary Share
Mason Capital Management LLC, a Delaware limited liability company ("Mason Capital"), announced today that it has commenced a tender offer (the "Tender Offer") for any and all the outstanding ADSs and Ordinary Shares in Forward Pharma A/S (the...

at 20:30
BRAEMAR HOTELS & RESORTS UPDATES STOCKHOLDERS THAT 'ACTIVIST' BLACKWELLS CAPITAL'S ATTEMPTED WITHHOLD PROXY CAMPAIGN AT ASHFORD TRUST HAS FAILED
Braemar Hotels & Resorts Inc. ("Braemar" or the "Company") today announced that, based on estimated preliminary results, Blackwells Capital LLC's ("Blackwells") withhold proxy campaign at Ashford Hospitality Trust, Inc. ("Ashford Trust") proved to...

at 20:25
ASHFORD HOSPITALITY TRUST ANNOUNCES PRELIMINARY RESULTS OF ITS 2024 ANNUAL MEETING OF STOCKHOLDERS 'ACTIVIST' BLACKWELLS EFFORTS THWARTED
Ashford Hospitality Trust, Inc. ("Ashford Trust" or the "Company") is pleased to report estimated preliminary results of its 2024 Annual Meeting of Stockholders and noted that Blackwells Capital LLC's ("Blackwells") attempted withhold proxy campaign...

at 20:23
Sagicor Financial Reports First Quarter 2024 Results and Announces Meeting of Shareholders, Availability of 2023 Management Information Circular, Annual Report and Annual Information Form
This news release for Sagicor Financial Company Ltd. ("Sagicor Financial" or "Sagicor" or the "Company") should be read in conjunction with the Company's Management's Discussion & Analysis ("MD&A") and the Condensed Consolidated Financial Statements...

More news about Business...


News published on and distributed by: